PRIMARY STUDY
Cannabinoids and Chronic Liver Diseases
Key Findings: This review suggests that certain pathways in the endocannabinoid system (eCBS) of the liver may provide therapeutic options for certain chronic liver diseases(CLD). Experimental models and observational studies of CLD suggest that cannabis and cannabinoids may be hepatoprotective CLDs through multiple pathways.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Canada, Italy
Year of Pub: 2020
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Cannabinoid (unspecified), Endocannabinoid (unspecified), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB2, GPCR 18, GPCR 55, TRPA1, TRPV1, TRPV2, TRPM8, PPAR - Alpha, PPAR - Gamma, TRPs, PPARs
Ligands Studied: Pro-inflammatory cytokines
Citation: Mboumba Bouassa RS, et al. Cannabinoids and Chronic Liver Diseases. Int J Mol Sci. 2022; 23:(unknown pages). doi: 10.3390/ijms23169423
Authors: Mboumba Bouassa RS, Sebastiani G, Di Marzo V, Jenabian MA, Costiniuk CT
